In a bid to boost the global competitiveness of Indian accounting and advisory firms, the government has announced a dual-pronged reform: simplifying the 'accountant' definition under Safe Harbour Rules and merging tax computation standards with financial reporting norms.
Amid a market environment of stable rates and mixed sentiment, we highlight three companies—spanning biotech, gaming, and tech hardware—whose current share prices appear significantly below their estimated intrinsic value based on cash flow projections.
While Italtile's stock saw an 11% bump last month, a look at the past five years reveals a sobering picture for long-term investors, with total shareholder returns deep in negative territory even as company earnings grew.
Japan's financial giant Nomura Holdings is scaling back risk at its digital asset unit following Q3 losses, a strategic pullback that mirrors wider pain across the crypto treasury sector as Bitcoin struggles to hold key levels.
Russian forces have reportedly seized the settlement of Prydorozhnie in southeastern Ukraine's Zaporizhzhia region, according to a defense ministry statement. The claim, yet to be independently verified, marks the latest in a series of incremental territorial gains.
Immunocore Holdings (IMCR) shares have experienced notable turbulence, declining over 7% in a week. Yet, a significant gap between its current price and analyst fair value estimates highlights a debate over the biotech's future, heavily reliant on its lead asset KIMMTRAK and pipeline execution.
Shares of tower REIT SBA Communications (SBAC) have faced sustained pressure, declining across multiple timeframes. With the stock trading significantly below common fair value estimates, analysts and investors are divided on whether this presents a buying opportunity or reflects deeper sector headwinds.
Thiel Macro, the hedge fund managed by Palantir co-founder Peter Thiel, has made a decisive shift in its investment strategy, exiting Nvidia and reducing Tesla while building massive positions in Apple and Microsoft, which together now constitute over 60% of its holdings.
While trading near 52-week highs can signal strength, it can also precede a correction. We examine three stocks where current valuations may not justify the price tag, urging investors to look beyond the hype.
Singapore will establish its National Space Agency on April 1st, aiming to leverage its technological prowess to secure a strategic position in the rapidly expanding global space economy, as global investments continue to soar.
CrossCurve's cross-chain bridge was exploited on February 2, leading to an estimated $3 million loss. The incident underscores the recurring security challenges within decentralized finance's bridging infrastructure.
Ethereum's price has plunged 27% in five days, bringing it perilously close to the $2,000 threshold. While fear-driven selling dominates, on-chain metrics suggest the sell-off may be nearing exhaustion, potentially setting the stage for a long-term recovery.
Havana denies White House accusations of being a security threat while appealing for constructive talks, as U.S. pressure cuts off vital Venezuelan oil supplies and risks a humanitarian crisis.
After a stellar 365% surge in the past three years, XRP faces a challenging horizon. Economic uncertainty, shifting investor sentiment, and the maturation of key growth drivers suggest a potentially turbulent period ahead for the digital asset.
New Gold Inc. shareholders have overwhelmingly approved the planned acquisition by Coeur Mining, a move set to create a leading, diversified precious metals producer focused entirely in North America. The deal, valued through a share swap, is anticipated to close in mid-2026.
Cogent Biosciences secures a key FDA Breakthrough Therapy Designation for its bezuclastinib-sunitinib combination in advanced GIST, following promising Phase 3 data that showed a halving of disease progression risk.
Aerospace systems provider Astronics Corporation launches its new automated circuit card testing system, designed to accelerate troubleshooting and maintenance for critical aviation and defense electronics, as analysts raise price targets on sustained sector demand.
Erasca (ERAS) gains significant analyst momentum as Mizuho initiates coverage with an 'Outperform' rating and a $16 price target, citing confidence in its 2026 proof-of-concept milestones for RAS-targeted cancer therapies.
Terns Pharmaceuticals has restructured a key licensing deal with China's Hansoh, gaining exclusive worldwide rights for its TERN-701 oncology drug outside Greater China. The strategic move, coupled with a recent analyst price target surge, signals the company's aggressive push into international markets.
ABIVAX (NASDAQ:ABVX) shares have skyrocketed over 2000% in recent months, fueled by speculation of an Eli Lilly buyout and promising clinical data for its lead drug. CEO Marc De Garidel has publicly dismissed the acquisition rumors as 'noise,' redirecting focus to the company's financing needs and advancing therapeutic programs.
